Primary biliary cholangitis : therapeutic and evolving aspects about 46 cases

##plugins.themes.academic_pro.article.sidebar##

Published Jun 11, 2018
Download
pdf
Vol. 96 No. 1 (2018): Issue Jan 2018

##plugins.themes.academic_pro.article.main##

Mohamed Hichem Loghmari
Donia Jemmali
Wafa Ben Mansour
Arwa Guediche
Wided Bouhlel
Leila Safer

Abstract

Background: Primary biliary cholangitis (PBC) is a rare autoimmune chronic liver disease whose prevalence is increasing. Medical treatment is based on ursodeoxycholic acid. It association with autoimmune hepatitis defined the overlap syndrome (OS).
Aim: It was to determine therapeutic and evolving characteristics of PBC and to compare them to those in subjects having an overlap syndrome.
Methods: This was a retrospective study of all the patients’ files with PBC from hepato-gastroenterology department at Monastir hospital from April 1999 to November 2013.
Results: Forty six patients were included in our study: 43 women and 3 men with an average age of 55 years. OS was retained in 13 patients. Cirrhosis was retained in 21 patients. Thirty-eight patients were treated with ursodeoxycholic acid (UDCA) associated with corticosteroids and immunosuppressors in the case of OS. After an average follow-up of 50 months [13-169 months] the overall response rate to UDCA was 55%. This rate was comparable between the 2 groups isolated PBC and OS. It was lower in the cirrhosis group compared with non-cirrhotic patients (40% vs 65%, p=0,06). One patient underwent a liver transplantation. Three patients were died as a result of decompensated cirrhosis.
Conclusion: Our study highlights the frequency of cirrhosis at the time of PBC diagnosis, which may explain the low rate of response to UDCA. There is no difference in the therapeutic and evolving aspects between patients with isolated PBC and those with SC.

Keywords:

Hepatology, Primary biliary cholangitis, overlap syndrome, ursodeoxycholic acid, liver transplantation

##plugins.themes.academic_pro.article.details##

References

  1. Parés A. Old and novel therapies for primary biliary cirrhosis. Semin Liver Dis. 2014;34(3):341-51.
  2. Lazaridis, Talwalker JA. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol. 2007;41(5):494-500.
  3. Chazouillères O, Wendum D. Diseases of the intrahepatic bile duct: diagnosis and principles of treatment. Gastroenterol Clin Biol. 2003;27(3):307-18.
  4. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis - autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28(2):296-301.
  5. J scheuer P. Primary biliary cirrhosis. Proc. R. Soc. med 1967;60:1257-60.
  6. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130(20):715-20.
  7. Prince M I, Chetwynd A, Craig W L, Metcalf J V, James O F W. Asymptomatic primary biliary cirrhosis: clinical features,prognosis, and symptom progression in a large population based cohort. Gut 2004;53:865-870.
  8. Nguyen-Khac E, Kairis L, Gournay N, et al. Paris J-C, Dupas J-L. « Overlap syndrome » ou syndrome de chevauchement entre cirrhose biliaire primitive et hépatite auto-immune. Gastroenterol Clin Biol 2004; 28:1107-1116.
  9. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary Biliary Cirrhosis: AASLD practice guidelines. Hepatology 2009; 50 (1)
  10. European Association for the Study of the Liver clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-67.
  11. European Association for the Study of the Liver Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of Hepatology 2017 vol. 67 j 145-172.
  12. Tabibian JH, Lindor KD. Primary biliary cirrhosis: safety and benefits of established and emerging therapies. Expert Opin Drug Saf. 2015;14(9):1-10.
  13. Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmun Rev. 2014;13(4):441-4.
  14. Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010;52(1):349-59.
  15. Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;6(1):1-39.
  16. Pagán B, Erdozain JC, Comas C, Martín-Chávarri S, López M, Gómez-Cerezo JF. Budesonide combined with ursodeoxycholic acid in primary biliary cirrhosis with advanced liver damage. Eur J Intern Med. 2006;17(7):508-10.
  17. Nevens F, Andreone P, Mazzella G, et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 2016;375:631-43.
  18. Ozaslan E, Cumali E, Heurgué-Berlot A, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2014;12(5):863-9.
  19. Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;144(3):560-9.
  20. Levy C, Naik J, Giordano C, et al. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics. Clin Gastroenterol Hepatol. 2014;12(8):1398-405.
  21. Kuiper EM, Hansen BE, De Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136(4):1281-7.
  22. Raczyńska J, Habior A, Pączek L, Foroncewicz B, Pawełas A, Mucha K. Primary biliary cirrhosis in the era of liver transplantation. Ann Transplant. 2014;19(1):488-93.
  23. Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2007;5(11):1313-5.
  24. Kuiper E, Hansen BE, Metselaar HJ, et al. Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. BMC Gastroenterol. 2010;10(1):144.
  25. Bosch A, Dumortier J, Maucort-Boulch D, et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. J Hepatol. 2015;63(6):1449-58.
  26. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid andlong-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871-7.
  27. Lammers WJ, Kowdley KV, Van Buuren HR. Predicting outcome in primary biliary cirrhosis. Annals of hepatology July-August 2014; 13 (4): 316-326.
  28. Jones DE, Al-Rifai A, Frith J, Patanwala I, Newton JL. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up. J Hepatol. 2010;53(5):911-7.